Edition:
India

Bioverativ Inc (BIVV.OQ)

BIVV.OQ on NASDAQ Stock Exchange Global Select Market

103.61USD
16 Feb 2018
Change (% chg)

$0.07 (+0.07%)
Prev Close
$103.54
Open
$103.48
Day's High
$103.75
Day's Low
$103.40
Volume
258,043
Avg. Vol
551,056
52-wk High
$104.30
52-wk Low
$43.55

Chart for

About

Bioverativ Inc. (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein],... (more)

Overall

Beta: --
Market Cap(Mil.): $6,375.17
Shares Outstanding(Mil.): 108.18
Dividend: --
Yield (%): --

Financials

BRIEF-Bioverativ Q4 Revenue Rose 28.3 Percent To $328.7 Million

* BIOVERATIV REPORTS FOURTH QUARTER AND FULL YEAR 2017 PERFORMANCE

14 Feb 2018

BRIEF-Sanofi Commences Tender Offer For Acquisition Of Bioverativ

* SANOFI COMMENCES TENDER OFFER FOR ACQUISITION OF BIOVERATIV INC.

08 Feb 2018

Healthcare group Sanofi to buy Ablynx for 3.9 billion euros

PARIS, Jan 29 Sanofi has agreed to buy Belgian biotech company Ablynx for 3.9 billion euros ($4.8 billion), the companies said on Monday, marking the French drug maker's second major takeover deal this month following its acquisition of Bioverativ.

29 Jan 2018

U.S. SEC files suit over possible insider trading on Bioverativ

The U.S. Securities and Exchange Commission filed an insider trading lawsuit on Friday against "unknown traders" who it said engaged in "highly suspicious trading" just ahead of the announcement that hemophilia specialist Bioverativ Inc had agreed to be acquired by France's Sanofi in an $11.6 billion deal.

27 Jan 2018

U.S. SEC files suit over possible insider trading on Bioverativ

Jan 26 The U.S. Securities and Exchange Commission filed an insider trading lawsuit on Friday against "unknown traders" who it said engaged in "highly suspicious trading" just ahead of the announcement that hemophilia specialist Bioverativ Inc had agreed to be acquired by France's Sanofi in an $11.6 billion deal.

27 Jan 2018

Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion

PARIS French healthcare group Sanofi has agreed to buy U.S. haemophilia specialist Bioverativ for $11.6 billion, its biggest deal for seven years and a major play to strengthen its presence in treatments for rare diseases. | Video

22 Jan 2018

New drugs recast $10 billion haemophilia market as Sanofi swoops in

LONDON Sanofi is placing a big bet on the $10 billion-a-year haemophilia market at a testing time, as scientific advances overhaul traditional approaches to treating the rare uncontrolled bleeding disorder. | Video

22 Jan 2018

Sanofi digs deep to buy U.S. hemophilia group Bioverativ for $11.6 billion

PARIS French healthcare group Sanofi has agreed to buy U.S. hemophilia specialist Bioverativ for $11.6 billion, its biggest deal for seven years and a major play to strengthen its presence in treatments for rare diseases. | Video

22 Jan 2018

UPDATE 5-Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 bln

* Shares in Sanofi down 4 percent (Updates shares, adds links to Breakingviews and other stories)

22 Jan 2018

BRIEF-Sanofi CFO sees commercial, cost and tax synergies following Bioverativ deal

Jan 22 Sanofi Chief financial officer Jerome Contamine says :

22 Jan 2018

Earnings vs. Estimates